As Hutchmed awaits FDA ap­proval for su­r­u­fa­tinib, drug gets the go-ahead in Chi­na; SCO­TUS knocks back last Amarin patent bid

Chi­nese reg­u­la­tors on Fri­day signed off on the sec­ond ap­proval for Hutchmed’s on­col­o­gy drug su­r­u­fa­tinib af­ter a suc­cess­ful Phase III tri­al.

Known com­mer­cial­ly as Su­lan­da …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER